Phytochemical and pharmacological evaluation of the fruits of averrhoa bilimbi
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Plants have played a major role in the treatment of various diseases and
newlinedisorders in human beings. Many of the novel drugs used now days were derived
newlinefrom the active principles of medicinal plants. Averrhoa bilimbi is such a plant. It is a
newlinemultipurpose, long lived tropical plant commonly known as bilimbi. The whole plant
newlineis useful. The fruits of the plant are rich in flavanoids and can be used as antidiabetic
newlineand antihyperlipidemic agent. Although a work had been carried out to evaluate the
newlineanti diabetic properties of the leaves of the selected plant, by Peter Nateshan
newlinePushparaj et al., and Ambili A S et al., studied the anti hyperlipedimic activity fruits
newlineof the selected plant, an exhaustive study on the phytochemical quot and
newline pharmacological aspects with respect to the antidiabetic and anti hyperlipidemic
newlineactivity of the fruit, which is edible, has not yet been carried out. The aim of this
newlineresearch work is focused on the phytochemical and pharmacological evaluation of the
newlinevarious extracts of A. bilimbi for its anti-diabetic and anti-hyperlipidemic activity.
newlineThe purpose of this research work is to validate the traditional claims on the health
newlinebeneficial effects of the selected plant with the help of modern scientific tools. The
newlinephytochemical screening of the fruit by HPTLC method revealed a marker compound
newlinewith Rf 0.24 and further characterization using LCMS,13C and 1H NMR and FTIR
newlinestudies tentatively confirmed it to be Dihydromyricetin with a molecular formula of
newlineC15H12O8. Pharmacological screening of the marker compound revealed that it can
newlineconsiderably lower the blood glucose level in alloxan induced diabetic rats in
newlinecomparison with the standard drug Metformin and blood lipidemic level in triton
newlineinduced hyperlipidemic rats in comparison with standard drug simvastatin.
newline